Biotech Values

[DewDiligence]

MGTA reverse-merges with—(private)—Dianthus Therapeutics:

https://www.globenewswire.com/news-release/2023/05/03/2660170/0/en/Magenta-Therapeutics-and-Dianthus-Therapeutics-Announce-Merger-Agreement.html

The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103 currently in a Phase 1 clinical trial. Upon completion of the merger, the combined company is expected to operate under the name Dianthus Therapeutics, Inc. and trade on the Nasdaq under the ticker symbol “DNTH”.

…Pre-merger Dianthus stockholders…are expected to own approximately 78.7% of the combined company and pre-merger Magenta stockholders are expected to own approximately 21.3% of the combined company.

This kind of deal was telegraphed three months ago when MGTA ceased all clinical development (#msg-171107083).